You are here

INVOKANA® monotherapy demonstrated significantly greater reductions in A1C vs placebo at 26 weeks1

Adjusted Mean Change in A1C From Baseline at 26 Weeks (%)


Reductions in A1C: INVOKANA® monotherapy vs placeboReductions in A1C: INVOKANA® monotherapy vs placebo
  • INVOKANA® 100 mg difference from placebo: –0.91% (95% CI: –1.09, –0.73; P <0.001)
  • INVOKANA® 300 mg difference from placebo: –1.16% (95% CI: –1.34, –0.99; P <0.001)

Secondary endpoint: Percent of patients who achieved the A1C goal of <7.0% vs placebo at 26 weeks1,2

  • 45% with INVOKANA® 100 mg*
  • 62% with INVOKANA® 300 mg*
  • 21% with placebo

INVOKANA® should not be initiated in patients with an eGFR <45 mL/min/1.73 m2.

Study Design

The efficacy and safety of INVOKANA® monotherapy were assessed in subjects with type 2 diabetes mellitus who were inadequately controlled with diet and exercise. In this 26-week, double-blind, placebo-controlled study, 584 patients were randomized to receive placebo (n=192), INVOKANA® 100 mg (n=195), or INVOKANA® 300 mg (n=197). Mean baseline A1C values were, respectively, 7.97%, 8.06%, and 8.01%. The primary endpoint was the change in A1C from baseline to week 26. Prespecified secondary endpoints included change in fasting plasma glucose, change in percent body weight, and change in systolic blood pressure.1,3

*P <0.001 vs placebo.

See the results of INVOKANA® VS JANUVIA®, VS GLIMEPIRIDE, in PATIENTS WITH RENAL IMPAIRMENT, and in OLDER PATIENTS.

References: 1. INVOKANA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-149. 3. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372-382.